



## New Pharmacologic Approaches to Study and Intervene in Epithelial to Mesenchymal Transition (EMT) and Fibrosis

Guest Editors:

**Dr. Raffaele Strippoli**

**Dr. Marco Cordani**

**Dr. Sergio Valente**

**Dr. Marco Tafani**

Deadline for manuscript  
submissions:

**closed (31 March 2022)**

### Message from the Guest Editors

Fibrosis is a general mechanism of response to a wide range of insults and is characterized by abnormal production and remodeling of extracellular matrix proteins. This process is regulated by a number of extracellular mediators and deeply impacts cell behavior through changes in mechanosensing, cellular plasticity and cell-to-cell communication.

Importantly, due to the incomplete ability of endogenous mechanisms to remove the fibrotic deposits, and since no resolute therapies are available to date, the persistence of profibrotic conditions may cause scarring and thickening of the affected tissue with persistent organ damage and loss of function.

The journal *Pharmaceuticals* invites both reviews and original articles shedding light on the challenges and opportunities of pharmacological treatment of every aspect of fibrosis. Topics include rational of pharmacological treatment for EMT–MET dynamics, control of fibrosis by autophagy, oxidative response, hypoxia, epigenetic mechanisms, new drugs, and new methods of pharmacological delivery, including nanomedicine.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química e Bioquímica (CQB), Faculdade de Ciências, Universidade de Lisboa (FCUL), Rua Ernesto de Vasconcelos, Campo Grande, Edifício C8, 5º Piso, 1749-016 Lisboa, Portugal

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

*Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

---

*Pharmaceuticals* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceuticals](http://mdpi.com/journal/pharmaceuticals)  
[pharmaceuticals@mdpi.com](mailto:pharmaceuticals@mdpi.com)